[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hayatabad Medical Complex\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":133},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,70,90,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100633138","phase-4-comparison-between-efficacy-of-topical-tranexamic-acid-vs-topical-ethyl-ascorbic-acid-in-treatment-of-melasma-100633138",false,"NCT07522788","Comparison Between Efficacy of Topical Tranexamic Acid Vs Topical Ethyl Ascorbic Acid In Treatment Of Melasma","Inclusion Criteria:\n\n* Adults age 18 to 50 years Clinically diagnosed Melasma Irrespective of gender and ethnicity\n\nExclusion Criteria:\n\n* pregnant and lactating women Patients with a history of skin allergies to study medications Use of systemic steroides or anti coagulants within the last month Patients on other melasma treatments for atleast 4 weeks prior",true,"ALL","18 Years","50 Years",{"count":20,"type":21},128,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study is to compare the efficacy of topical tranexamic acid vs topical ethyl ascorbic acid in the treatment of melasma",[27],"Melasma",[27],"NOT_YET_RECRUITING","2026-04-04",{"date":32,"type":33},"2026-04-13","ACTUAL",{"date":35,"type":21},"2026-06-01",{"date":37,"type":21},"2026-11-30",{"name":39,"class":40},"Hayatabad Medical Complex","OTHER_GOV",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100628316","comparison-of-two-sedative-agents-in-terms-of-controlled-hypotension-100628316","NCT07460050","Comparison of Two Sedative Agents in Terms of Controlled Hypotension","COMPARISON OF PROPOFOL INFUSION VS INHALATIONAL AGENT ISOFLURANE IN TERMS OF CONTROLLED HYPOTENSION IN PATIENTS UNDERGOING ENDOSCOPIC SINUS SURGERY","Inclusion Criteria:\n\n* Either male\u002Ffemale Age 18-65 Patients undergoing endoscopic sinus surgery as per the operational definition\n\nExclusion Criteria:\n\n* Patients with cardiovascular disease Patients with pregnancy Patients with coagulopathy Patients on beta blockers or calcium channel blockers","65 Years",{"count":50,"type":21},136,[52],"NA","Propofol and Isoflurane are commonly used sedative agents in general anaesthesia.Both these drugs have a side effect of decreasing blood pressure which when used optimally can be used to acheive controlled hypotention. So, it provides a better visiblity of surgical filed to the surgeons.This RCT compares propofol infusion vs isoflurane inhalation for inducing controlled hypotension during endoscopic sinus surgery. The goal is to assess which agent better controls blood pressure, improves surgical field visibility, and impacts recovery. It likely measures outcomes like hemodynamics, bleeding, and surgeon satisfaction.",[55],"Controlled Hypotension for Nasal Surgeries",[57,58,59,60],"Controlled hypotention","Propofol infusion","Endoscopic sinus surgery","Isoflurane inhalation","2026-03-04",{"date":63,"type":33},"2026-03-10",{"date":65,"type":21},"2026-03-01",{"date":67,"type":21},"2026-08-01",{"name":39,"class":40},1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":88,"leadSponsor":89,"locationsCount":4},"100625432","intravenous-nalbuphine-versus-lidocaine-for-prevention-of-propofol-injection-pain-100625432","NCT07422558","Intravenous Nalbuphine Versus Lidocaine for Prevention of Propofol Injection Pain","Comprasion of Intravenous Nalbuphine Versus Lidocaine in Reducing Propofol -Induced Injection Pain During General Surgery Procedure","Inclusion Criteria:\n\n* Age 18-60 years\n\n  * Either male or female\n  * ASA physical status I or II\n  * Scheduled for elective general surgery under general anesthesia using propofol\n\nExclusion Criteria:\n\n* Known hypersensitivity to propofol, nalbuphine, or lidocaine\n\n  * Emergency surgery\n  * Use of analgesics prior to surgery\n  * Pregnant women\n  * Lactating women","60 Years",{"count":79,"type":21},92,[52],"Propofol is a commonly used intravenous anesthetic agent, but its administration is frequently associated with injection pain, causing patient discomfort and agitation. Various pharmacological agents have been used to reduce this pain, including nalbuphine and lidocaine; however, results from previous studies remain conflicting. This randomized clinical trial aims to compare the effectiveness of intravenous nalbuphine versus intravenous lidocaine in reducing the frequency of propofol-induced injection pain in patients undergoing elective general surgery procedures.",[83],"Procedural Pain","2026-02-13",{"date":86,"type":33},"2026-02-20",{"date":65,"type":21},{"date":67,"type":21},{"name":39,"class":40},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":4},"100610884","assessing-the-efficacy-of-probiotics-in-prevention-of-nec-in-preterm-babies-100610884","NCT07233382","Assessing the Efficacy of Probiotics in Prevention of NEC in Preterm Babies","Inclusion Criteria:\n\n* Male and female preterm infants with a gestational age less than 35 weeks.\n* All indoor patients and outdoor patients who present within 24hrs of birth\n\nExclusion Criteria:\n\n* • Infants with congenital or developmental gastrointestinal disorders for example omphalocele, malrotation, gastroschisis.\n\n  * Infants with severe sepsis or gastrointestinal bleeding on presentation","1 Day",{"count":98,"type":21},196,[52],"The goal of the study is to check efficacy of probiotics in preventing necrotizing enterocolitis. The main questions would be if the preterm baby developed NEC or not.",[102,103],"NEC","NEC - Necrotizing Enterocolitis","2025-11-28",{"date":106,"type":33},"2025-12-05",{"date":108,"type":21},"2025-12-01",{"date":110,"type":21},"2026-05-30",{"name":39,"class":40},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":69},"100588570","phase-4-comparison-of-efficacy-of-35-glycolic-acid-vs-20-salicylic-acid-peel-in-the-treatment-of-post-acne-scars-100588570","NCT06943118","Comparison of Efficacy of 35% Glycolic Acid vs 20% Salicylic Acid Peel in the Treatment of Post Acne Scars","Inclusion Criteria:\n\n* Patients aged 18-45 years with mild to moderate atrophic post acne scars\n* Fitzpatrick skin type 2-4\n* No active acne or ongoing systemic acne treatment\n\nExclusion Criteria:\n\n* Pregnancy and breast feeding\n* History of keloid or hypertrophic scars\n* Use of retinoids or chemical peel in last 3 months\n* Active skin infections\n* History of hyperpigmentation after any procedure\n* Hypersensitivity to aspirin","45 Years",{"count":120,"type":21},60,[24],"The goal of this clinical trial is to compare the effectiveness of two drugs in patients that presents with scars on face after acnes. The effectiveness will be measured by a goodman and baron scale. One group of patients will receive 35% glycolic acid while other group of patients will receive 20% salicylic acid and both groups will be followed by 12 weeks.",[124],"Post Acne Scars","2025-04-17",{"date":127,"type":33},"2025-04-24",{"date":129,"type":21},"2025-04",{"date":131,"type":21},"2025-10",{"name":39,"class":40},""]